<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 25 Mar 2021 10:28:22 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>华夏英泰：STAR-T对于实体瘤极具潜力</title><link>https://mp.weixin.qq.com/s/_x0Uz8PXpyEV9awshETtCQ</link><description></description><content:encoded><![CDATA[华夏英泰：STAR-T对于实体瘤极具潜力]]></content:encoded><pubDate>Thu, 25 Mar 2021 10:08:41 +0800</pubDate></item><item><title>三特异性CAR-T：CD19/CD20/CD22</title><link>https://mp.weixin.qq.com/s/pkqH_fLbKBpBpKEqAEqe5g</link><description></description><content:encoded><![CDATA[三特异性CAR-T：CD19/CD20/CD22]]></content:encoded><pubDate>Thu, 25 Mar 2021 10:08:41 +0800</pubDate></item><item><title>百奥泰二次递表港股IPO：ADC全军覆没之后，强化双抗布局</title><link>https://mp.weixin.qq.com/s/rNnYXXuPHrgNVBqba6Xknw</link><description></description><content:encoded><![CDATA[百奥泰二次递表港股IPO：ADC全军覆没之后，强化双抗布局]]></content:encoded><pubDate>Tue, 23 Mar 2021 23:27:14 +0800</pubDate></item><item><title>盘点三地上市的中国生物医药企业</title><link>https://mp.weixin.qq.com/s/hxwB9S7PMRMMHncD5LRfVA</link><description></description><content:encoded><![CDATA[盘点三地上市的中国生物医药企业]]></content:encoded><pubDate>Tue, 23 Mar 2021 10:42:36 +0800</pubDate></item><item><title>抑制性白细胞免疫球蛋白样受体：LILRB</title><link>https://mp.weixin.qq.com/s/6l-81xplg9DPpIPLNx0EeA</link><description></description><content:encoded><![CDATA[抑制性白细胞免疫球蛋白样受体：LILRB]]></content:encoded><pubDate>Tue, 23 Mar 2021 10:42:36 +0800</pubDate></item><item><title>大分子CDMO乘风破浪：原核、抗体、基因治疗</title><link>https://mp.weixin.qq.com/s/QDdzmuawFXYE6ZmTHm5YAQ</link><description></description><content:encoded><![CDATA[大分子CDMO乘风破浪：原核、抗体、基因治疗]]></content:encoded><pubDate>Mon, 22 Mar 2021 13:19:48 +0800</pubDate></item><item><title>康乃德今日美股上市，首日股价上涨30%</title><link>https://mp.weixin.qq.com/s/zjLfMJhA1juBr9euYdf3KA</link><description></description><content:encoded><![CDATA[康乃德今日美股上市，首日股价上涨30%]]></content:encoded><pubDate>Fri, 19 Mar 2021 23:15:22 +0800</pubDate></item><item><title>CAR-M完成首例给药，进军HER2实体瘤</title><link>https://mp.weixin.qq.com/s/A7ETqVSZ-E0v2Pxi33p0ag</link><description></description><content:encoded><![CDATA[CAR-M完成首例给药，进军HER2实体瘤]]></content:encoded><pubDate>Fri, 19 Mar 2021 07:07:07 +0800</pubDate></item><item><title>上交大医疗未来领袖第五期，打造独一无二的价值课程和平台</title><link>https://mp.weixin.qq.com/s/V6q65dGKGFXexp6yDEAATQ</link><description></description><content:encoded><![CDATA[上交大医疗未来领袖第五期，打造独一无二的价值课程和平台]]></content:encoded><pubDate>Fri, 19 Mar 2021 07:07:07 +0800</pubDate></item><item><title>Nature：预计年内超15款PROTAC进入临床</title><link>https://mp.weixin.qq.com/s/qoVHyTJd6lc44sYiKdd6mQ</link><description></description><content:encoded><![CDATA[Nature：预计年内超15款PROTAC进入临床]]></content:encoded><pubDate>Fri, 19 Mar 2021 07:07:07 +0800</pubDate></item><item><title>Christopher Garcia开发偏向性IL-10，或可用于自身免疫病</title><link>https://mp.weixin.qq.com/s/sj9DtI0lDlSHM9ANoC5k9A</link><description></description><content:encoded><![CDATA[Christopher Garcia开发偏向性IL-10，或可用于自身免疫病]]></content:encoded><pubDate>Fri, 19 Mar 2021 07:07:07 +0800</pubDate></item><item><title>国内首个：嘉和生物CD3/CD20双抗申报临床</title><link>https://mp.weixin.qq.com/s/ia6OjJd3ygb5IpNnfkNVHg</link><description></description><content:encoded><![CDATA[国内首个：嘉和生物CD3/CD20双抗申报临床]]></content:encoded><pubDate>Thu, 18 Mar 2021 10:27:12 +0800</pubDate></item><item><title>CCR8 目前尚无一例进入临床的热门靶点？</title><link>https://mp.weixin.qq.com/s/2Ri9UqqOvWYkkS2mxKkh7Q</link><description></description><content:encoded><![CDATA[CCR8 目前尚无一例进入临床的热门靶点？]]></content:encoded><pubDate>Thu, 18 Mar 2021 10:27:12 +0800</pubDate></item><item><title>恒瑞医药研发CD38抗体、IL-4R抗体</title><link>https://mp.weixin.qq.com/s/zrQIA5Fw321glRW9LtLd4g</link><description></description><content:encoded><![CDATA[恒瑞医药研发CD38抗体、IL-4R抗体]]></content:encoded><pubDate>Thu, 18 Mar 2021 10:27:12 +0800</pubDate></item><item><title>商业化前奏：突飞猛进的中国抗体药产能</title><link>https://mp.weixin.qq.com/s/81_1fV7vkIEC4GQrEazOAw</link><description></description><content:encoded><![CDATA[商业化前奏：突飞猛进的中国抗体药产能]]></content:encoded><pubDate>Thu, 18 Mar 2021 10:27:12 +0800</pubDate></item><item><title>ACC：抗体细胞偶联药物</title><link>https://mp.weixin.qq.com/s/IlRitHXtUfyRRXpUjZLlPQ</link><description></description><content:encoded><![CDATA[ACC：抗体细胞偶联药物]]></content:encoded><pubDate>Wed, 17 Mar 2021 09:56:15 +0800</pubDate></item><item><title>辉瑞小分子GLP-1R激动剂国内获批临床</title><link>https://mp.weixin.qq.com/s/f0UeoAI1p6CrvI7J6uCzGA</link><description></description><content:encoded><![CDATA[辉瑞小分子GLP-1R激动剂国内获批临床]]></content:encoded><pubDate>Wed, 17 Mar 2021 09:56:15 +0800</pubDate></item><item><title>首药控股科创板IPO，拟募资20亿元</title><link>https://mp.weixin.qq.com/s/Y0pAdiTHnQmdf9f4m9pHSQ</link><description></description><content:encoded><![CDATA[首药控股科创板IPO，拟募资20亿元]]></content:encoded><pubDate>Wed, 17 Mar 2021 09:56:15 +0800</pubDate></item><item><title>IL-7与肿瘤免疫治疗</title><link>https://mp.weixin.qq.com/s/XU5qYN-EsX-O1cD2gIoA5Q</link><description></description><content:encoded><![CDATA[IL-7与肿瘤免疫治疗]]></content:encoded><pubDate>Wed, 17 Mar 2021 09:56:15 +0800</pubDate></item><item><title>复宏汉霖CD73抗体启动临床，国内第3家</title><link>https://mp.weixin.qq.com/s/cZ30OPbYM489eKHNGcTpqA</link><description></description><content:encoded><![CDATA[复宏汉霖CD73抗体启动临床，国内第3家]]></content:encoded><pubDate>Tue, 16 Mar 2021 08:23:55 +0800</pubDate></item></channel></rss>